GO:0017134 fibroblast growth factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017134 (fibroblast growth factor binding) is a molecular function defined as binding to a fibroblast growth factor (FGF).
• FGF ligands signal through FGF receptors (FGFRs) in a heparan sulfate-dependent manner, and binding proteins such as Klotho convert canonical FGFs into endocrine hormones.
• The endocrine FGF subfamily (FGF19, FGF21, FGF23) requires α-Klotho or β-Klotho as obligate co-receptors, expanding the functional repertoire of FGF binding.
• Dysregulated FGF binding underlies cancers, chronic kidney disease, metabolic disorders, and bile acid dysregulation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect FGF ligand-receptor-co-receptor interactions.
• High-throughput CRISPR library screening and bioinformatics can identify novel modulators of FGF binding and signaling.
Description
Fibroblast growth factor (FGF) binding (GO:0017134) is a molecular function that mediates the initial recognition event between an FGF ligand and its binding partner, which can be a high-affinity FGF receptor (FGFR), a co-receptor such as a Klotho protein, or an extracellular matrix component. This binding event is the first committed step in FGF signal transduction, a pathway that controls proliferation, differentiation, survival, and metabolic homeostasis across diverse tissues. Because FGF signaling is pleiotropic, the specificity and affinity of FGF binding are tightly regulated at the level of ligand-receptor-co-receptor complex assembly. Researchers study GO:0017134 to understand how a relatively small family of ligands can elicit context-dependent biological outputs. The canonical paracrine FGFs (e.g., FGF1, FGF2, FGF4, FGF7) bind FGFRs with heparan sulfate proteoglycans as cofactors, whereas endocrine FGFs (FGF19, FGF21, FGF23) have reduced heparan sulfate affinity and instead require Klotho family proteins for stable receptor binding. This molecular switch is a paradigm for how binding specificity is achieved and how it can be targeted therapeutically. Dysregulation of FGF binding is implicated in a broad spectrum of human diseases, including cancer, chronic kidney disease, and metabolic syndrome. For example, FGF23 binding to the FGFR1–α-Klotho complex regulates phosphate and vitamin D metabolism, and its excess causes hypophosphatemic disorders. FGF19/FGF15 binding to FGFR4–β-Klotho controls bile acid synthesis, linking FGF binding to enterohepatic homeostasis. Thus, GO:0017134 is not merely a biochemical annotation but a central node in endocrine and paracrine physiology.
fibroblast growth factor binding At A Glance
| GO ID | GO:0017134 |
|---|---|
| GO term | fibroblast growth factor binding |
| Ontology | molecular_function |
| Synonym | FGF binding; FGF 1 binding; FGF 2 binding; FGF 3 binding; FGF 4 binding; FGF 5 binding; FGF 6 binding; fibroblast growth factor 1 binding; fibroblast growth factor 2 binding; fibroblast growth factor 3 binding; fibroblast growth factor 4 binding; fibroblast growth factor 5 binding; fibroblast growth factor 6 binding |
| Major function | Mediates the initial recognition of FGF ligands by receptors, co-receptors, and matrix molecules, initiating FGF signal transduction. |
| Major ligands | FGF1, FGF2, FGF4, FGF7, FGF19, FGF21, FGF23, and other FGF family members. |
| Major binding partners | FGFR1–4, α-Klotho, β-Klotho, heparan sulfate proteoglycans. |
| Disease relevance | Cancer, chronic kidney disease, metabolic disorders, bile acid dysregulation. |
What Is GO:0017134?
In our own words, GO:0017134 (fibroblast growth factor binding) describes the selective, non-covalent interaction between a protein and any member of the fibroblast growth factor family. This function is defined by the ability to physically associate with an FGF ligand, as opposed to binding to other growth factors or unrelated proteins. The QuickGO definition states: "Binding to a fibroblast growth factor." The term encompasses binding to FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, and other FGFs, and it is a molecular_function in the Gene Ontology.
Why Is fibroblast growth factor binding Important in Cell Biology?
GO:0017134 is important because it defines the molecular entry point for one of the most versatile signaling families in human biology. FGF binding specificity determines whether a signal is paracrine or endocrine, which receptor is activated, and which downstream pathway (e.g., MAPK/ERK, PI3K/AKT) is engaged. This specificity is exploited by nature through alternative splicing of FGFRs and through Klotho co-receptors, and it is frequently corrupted in disease. Understanding FGF binding at the structural and cellular level therefore informs drug design, biomarker discovery, and the development of CRISPR-based disease models.
• FGF binding initiates signaling cascades that control cell proliferation, differentiation, and survival.
• Endocrine FGFs (FGF19, FGF21, FGF23) require Klotho co-receptors for binding and signaling, linking GO:0017134 to systemic metabolism.
• FGF23–α-Klotho binding regulates phosphate and vitamin D homeostasis; its dysregulation causes chronic kidney disease and hypophosphatemic disorders.
• FGF19/FGF15 binding to FGFR4–β-Klotho suppresses bile acid synthesis, connecting FGF binding to enterohepatic physiology.
• Aberrant FGF binding is oncogenic in multiple cancers, making it a target for small-molecule inhibitors and antibodies.
• FGF21 binding and signaling influence macrophage actions and microRNA-33 expression, implicating FGF binding in inflammation and lipid metabolism.
• Keratinocyte growth factor (FGF7) binding to FGFR2IIIb is critical for epithelial repair and is studied in wound healing and cancer.
• CRISPR screens can identify genes that modulate FGF binding and signaling, accelerating target discovery.
Molecular Mechanism of fibroblast growth factor binding
Ligand recognition and receptor engagement
In simple terms: FGF ligands grab onto their receptors like a key fitting a lock, but they often need a helper molecule to hold them in place.
The binding of an FGF ligand to its receptor (FGFR) is the first step in FGF signaling. Canonical paracrine FGFs (e.g., FGF1, FGF2, FGF4) bind FGFRs with moderate affinity, and this interaction is stabilized by heparan sulfate proteoglycans (HSPGs) in the extracellular matrix. The formation of a ternary FGF–FGFR–heparan sulfate complex induces receptor dimerization and trans-autophosphorylation, leading to downstream MAPK/ERK and PI3K/AKT activation. This mechanism is conserved across FGF family members and is essential for processes such as angiogenesis, wound healing, and embryonic development.
Klotho co-receptor requirement for endocrine FGFs
In simple terms: Some FGFs, like FGF23 and FGF19, cannot bind their receptors well on their own; they need a co-receptor called Klotho to form a stable complex.
Endocrine FGFs (FGF19, FGF21, FGF23) have evolved reduced heparan sulfate affinity and instead rely on Klotho family proteins for high-affinity receptor binding. For example, FGF23 binds the FGFR1–α-Klotho complex with nanomolar affinity, and α-Klotho acts as a non-enzymatic molecular scaffold that directly contacts both FGF23 and FGFR1. Similarly, FGF19 and FGF21 require β-Klotho to bind FGFR4 and FGFR1c, respectively. This co-receptor dependency provides tissue specificity and is a key determinant of endocrine FGF function.
Heparan sulfate and matrix interactions
In simple terms: Heparan sulfate chains act like molecular glue that helps FGFs and their receptors stick together, especially for paracrine FGFs.
Heparan sulfate proteoglycans (HSPGs) are essential cofactors for canonical FGF–FGFR binding. They promote ligand-receptor complex assembly by bridging FGF and FGFR, and they protect FGFs from degradation. The sulfation pattern of heparan sulfate determines binding specificity and can modulate signaling output. In contrast, endocrine FGFs have low heparan sulfate affinity, which allows them to diffuse into the bloodstream and act as hormones.
Regulation of FGF binding by feedback and antagonists
In simple terms: Cells can turn FGF binding up or down using decoy receptors, binding proteins, and feedback loops.
FGF binding is regulated at multiple levels. Soluble FGFR ectodomains can act as decoys that sequester FGF ligands. FGF-binding proteins (FGFBPs) in the extracellular matrix can modulate ligand availability. Intracellularly, FGF signaling induces negative feedback regulators such as Sprouty and MAPK phosphatases that attenuate downstream responses. Additionally, microRNAs and transcriptional regulators can alter the expression of FGFs, FGFRs, and Klotho proteins, indirectly affecting binding. These regulatory layers ensure that FGF binding is context-dependent and transient.
Key Genes Involved in GO:0017134 fibroblast growth factor binding
The following genes encode proteins that directly or indirectly participate in fibroblast growth factor binding (GO:0017134), including FGF ligands, FGF receptors, Klotho co-receptors, and heparan sulfate biosynthesis enzymes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF1 | Canonical paracrine FGF ligand; binds all FGFRs | Studied in angiogenesis, wound healing, and cancer |
| FGF2 | Prototypic FGF ligand; binds FGFRs with heparan sulfate | Model ligand for FGF binding assays and signaling studies |
| FGF4 | Paracrine FGF ligand; binds FGFR1-4 | Implicated in development and cancer |
| FGF7 | Keratinocyte growth factor; binds FGFR2IIIb | Key mediator of epithelial repair and cancer |
| FGF19 | Endocrine FGF ligand; binds FGFR4–β-Klotho | Regulates bile acid synthesis and metabolism |
| FGF21 | Endocrine FGF ligand; binds FGFR1c–β-Klotho | Regulates glucose and lipid metabolism; affects macrophages |
| FGF23 | Endocrine FGF ligand; binds FGFR1–α-Klotho | Regulates phosphate and vitamin D homeostasis |
| FGFR1 | High-affinity receptor for multiple FGFs | Central to FGF binding and signaling |
| FGFR2 | Receptor for FGF7 and other FGFs | Epithelial repair and cancer |
| FGFR3 | Receptor for FGF1, FGF2, FGF4 | Skeletal development and cancer |
| FGFR4 | Receptor for FGF19 | Bile acid metabolism and liver cancer |
| KL | α-Klotho; co-receptor for FGF23 | Essential for FGF23 binding and phosphate homeostasis |
| KLB | β-Klotho; co-receptor for FGF19 and FGF21 | Mediates endocrine FGF binding and metabolic regulation |
| HSPG2 | Perlecan; heparan sulfate proteoglycan | Modulates FGF binding and signaling |
| EXT1 | Heparan sulfate biosynthesis enzyme | Affects FGF binding by altering heparan sulfate |
| EXT2 | Heparan sulfate biosynthesis enzyme | Affects FGF binding by altering heparan sulfate |
| SDC1 | Syndecan-1; heparan sulfate proteoglycan | Co-receptor for FGF binding |
How Is fibroblast growth factor binding Regulated?
FGF binding is regulated by multiple mechanisms. At the extracellular level, heparan sulfate proteoglycans and Klotho proteins act as co-receptors that enhance or enable binding. Soluble decoy receptors and FGF-binding proteins can sequester ligands and prevent receptor activation. At the intracellular level, FGF signaling induces negative feedback loops involving Sprouty proteins, MAPK phosphatases, and microRNAs that dampen the pathway. Transcriptional regulation of FGFs, FGFRs, and Klotho genes further modulates binding capacity in a tissue-specific manner.
fibroblast growth factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF23 | Chronic kidney disease, hypophosphatemia | KL knockout or point-mutation cell model; FGF23 knock-in |
| FGF19 | Bile acid dysregulation, hepatocellular carcinoma | FGFR4/KLB knockout; FGF19 overexpression |
| FGF21 | Metabolic syndrome, inflammation | KLB knockout; FGF21 overexpression |
| FGF7 | Epithelial repair, cancer | FGFR2 knockout; FGF7 overexpression |
| FGF2 | Angiogenesis, cancer | FGFR1 knockout; FGF2 knock-in |
FGF binding in cancer
Dysregulated FGF binding and signaling are oncogenic in many cancers. Amplification or mutation of FGFRs, overexpression of FGF ligands, and aberrant heparan sulfate modification can drive tumor proliferation and angiogenesis. For example, FGF19 binding to FGFR4–β-Klotho promotes hepatocellular carcinoma, and FGF7 (KGF) binding to FGFR2IIIb is implicated in epithelial cancers. Targeting FGF binding with small-molecule inhibitors or antibodies is an active therapeutic strategy.
FGF binding in chronic kidney disease and mineral metabolism
FGF23 binding to the FGFR1–α-Klotho complex is central to phosphate and vitamin D regulation. In chronic kidney disease, elevated FGF23 levels and impaired α-Klotho expression contribute to mineral bone disorder and cardiovascular complications. The molecular scaffold function of α-Klotho in FGF23 binding is a key determinant of endocrine FGF specificity.
FGF binding in metabolic and bile acid disorders
FGF19/FGF15 binding to FGFR4–β-Klotho suppresses bile acid synthesis, and its dysregulation is linked to cholestasis and metabolic syndrome. FGF21 binding to FGFR1c–β-Klotho regulates glucose and lipid metabolism, and FGF21 can inhibit microRNA-33 expression to affect macrophage actions. These endocrine FGF pathways are being explored for therapeutic modulation in diabetes and fatty liver disease.
From fibroblast growth factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KL abolish FGF23 binding? | KL knockout cell line (e.g., HEK293) |
| Does a point mutation in FGFR1 disrupt FGF23 binding? | FGFR1 point-mutation knock-in |
| Can β-Klotho overexpression enhance FGF19 binding? | KLB overexpression cell model |
| Does FGF21 binding require β-Klotho? | KLB knockout; FGF21 binding assay |
| Does heparan sulfate modification affect FGF2 binding? | EXT1/EXT2 knockout; FGF2 binding assay |
| Can a tagged FGF23 be used to track binding? | Tagged FGF23 knock-in |
How to Study the fibroblast growth factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | FGF–FGFR–Klotho interaction analysis |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Quantifying FGF binding affinity |
| ELISA | Protein-protein binding | High-throughput screening of FGF binding |
| ERK phosphorylation assay | Downstream signaling activation | Functional validation of FGF binding |
| Luciferase reporter assay | Transcriptional response to FGF | Measuring FGF signaling output |
| CRISPR knockout screen | Genes required for FGF binding/signaling | Identifying novel modulators |
| Cryo-EM | 3D structure of binding complex | Visualizing FGF23–FGFR1–α-Klotho |
| Proximity ligation assay | In situ protein interactions | Detecting FGF binding in cells |
Binding assays (SPR, ITC, ELISA)
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure the affinity and kinetics of FGF–receptor–co-receptor interactions. ELISA-based binding assays can quantify FGF binding to immobilized receptors or Klotho proteins. These methods are essential for validating CRISPR-generated mutations that affect binding.
Cell-based signaling assays
FGF binding is often assessed by downstream signaling readouts, such as ERK phosphorylation, luciferase reporter assays, or calcium flux. These assays can be performed in wild-type and CRISPR-edited cells to determine the functional consequences of altered binding.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens can identify genes that modulate FGF binding and signaling. Bioinformatics analysis of transcriptomic and proteomic data can reveal FGF binding networks and predict co-receptor dependencies.
Structural biology and imaging
Cryo-EM and X-ray crystallography have resolved the structure of the FGF23–FGFR1–α-Klotho complex, revealing the molecular basis of binding specificity. Fluorescence microscopy and proximity ligation assays can visualize FGF binding in cells.
How CRISPR Can Be Used to Study GO:0017134 fibroblast growth factor binding
Knockout
CRISPR knockout of FGF ligands, receptors, or co-receptors (e.g., KL, KLB, FGFR1) can abolish FGF binding and signaling, providing causal evidence for their roles. For example, KL knockout cells fail to bind FGF23 and do not activate downstream ERK.
Point Mutation
Point mutations in FGFR or Klotho genes can be introduced to dissect binding interfaces. For instance, mutations in the α-Klotho domain that contacts FGF23 can selectively disrupt binding without affecting protein stability. Such models are valuable for understanding disease-associated variants.
Knock-in
Knock-in of tagged FGF ligands (e.g., GFP-FGF23) allows real-time tracking of binding and trafficking. Knock-in of disease-relevant mutations (e.g., FGFR mutations) can model altered FGF binding in cancer or skeletal disorders.
Overexpression
Overexpression of FGFs or co-receptors (e.g., FGF19, KLB) can enhance binding and amplify signaling, useful for studying gain-of-function effects in metabolic and cancer models.
How EDITGENE Supports fibroblast growth factor binding Research
Researchers studying fibroblast growth factor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for fibroblast growth factor binding research.
Frequently Asked Questions About fibroblast growth factor binding
What is fibroblast growth factor binding (GO:0017134)?
GO:0017134 is a Gene Ontology molecular function defined as binding to a fibroblast growth factor. It encompasses the selective interaction between proteins and FGF ligands, initiating FGF signaling.
What genes are involved in fibroblast growth factor binding?
Key genes include FGF ligands (FGF1, FGF2, FGF4, FGF7, FGF19, FGF21, FGF23), FGF receptors (FGFR1-4), Klotho co-receptors (KL, KLB), and heparan sulfate proteoglycans (HSPG2, SDC1).
How does FGF23 bind to its receptor?
FGF23 binds the FGFR1–α-Klotho complex with high affinity, where α-Klotho acts as a non-enzymatic scaffold that directly contacts both FGF23 and FGFR1.
What is the role of Klotho in FGF binding?
Klotho proteins (α-Klotho and β-Klotho) are obligate co-receptors for endocrine FGFs, enabling high-affinity binding to FGFRs and providing tissue specificity.
Which diseases are linked to abnormal FGF binding?
Abnormal FGF binding is linked to cancer, chronic kidney disease, hypophosphatemia, bile acid disorders, and metabolic syndrome.
How can CRISPR be used to study FGF binding?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of FGF ligands, receptors, and co-receptors in binding and signaling.
What methods measure FGF binding affinity?
Surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and ELISA are commonly used to measure FGF binding affinity and kinetics.
Is FGF19 an endocrine hormone?
Yes, FGF19 (and its mouse ortholog FGF15) is an endocrine FGF that requires β-Klotho to bind FGFR4 and regulate bile acid homeostasis.
What is the difference between paracrine and endocrine FGFs?
Paracrine FGFs (e.g., FGF1, FGF2) bind FGFRs with heparan sulfate cofactors, while endocrine FGFs (FGF19, FGF21, FGF23) have low heparan sulfate affinity and require Klotho co-receptors.
Can FGF binding be targeted therapeutically?
Yes, small-molecule inhibitors, antibodies, and decoy receptors targeting FGF binding are under development for cancer and metabolic diseases.
Conclusion
GO:0017134 (fibroblast growth factor binding) is a fundamental molecular function that governs the specificity and activity of the FGF signaling network. From paracrine ligands like FGF2 and FGF7 to endocrine hormones like FGF19, FGF21, and FGF23, the binding event determines which receptors are engaged and which downstream pathways are activated. The requirement for Klotho co-receptors and heparan sulfate proteoglycans adds layers of regulation that are critical for tissue-specific and systemic responses. Dysregulation of FGF binding is implicated in cancer, chronic kidney disease, and metabolic disorders, making it a compelling target for therapeutic intervention. CRISPR-based cell models, combined with binding assays and bioinformatics, provide powerful tools to dissect these interactions and identify new drug targets. EDITGENE offers end-to-end services to accelerate such research.
References
- 1. Rivas LJ et al.. 2024. Fibroblast Growth Factor (FGF) 13.. Differentiation 140:100814 PMID: 39332965
- 2. Agrawal S et al.. 2021. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.. Curr Drug Targets 22(2):214-240 PMID: 33045958
- 3. Kuro-O M. 2019. The Klotho proteins in health and disease.. Nat Rev Nephrol 15(1):27-44 PMID: 30455427
- 4. Inagaki T et al.. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.. Cell Metab 2(4):217-25 PMID: 16213224
- 5. Guo Y et al.. 2016. Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions.. Lipids Health Dis 15(1):208 PMID: 27905947
- 6. Bouju A et al.. 2024. A primer on the pleiotropic endocrine fibroblast growth factor FGF19/FGF15.. Differentiation 140:100816 PMID: 39500656
- 7. Chen G et al.. 2018. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling.. Nature 553(7689):461-466 PMID: 29342138
- 8. Rubin JS et al.. 1995. Keratinocyte growth factor.. Cell Biol Int 19(5):399-411 PMID: 7640656
